Pfizer Inc

NYSE: PFE
$29.22
-$0.05 (-0.2%)
Closing Price on October 18, 2024

PFE Articles

The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
A few analysts released reports this past week calling for these three Dow stocks to rise even higher (at least 10%).
The DJIA was headed for a nearly flat close Thursday, with Pfizer and UnitedHealth offsetting share price declines at Apple and DuPont.
A few analysts released reports Wednesday calling for three Dow stocks to rise even higher. It seems at this rate that 23,000 is just around the corner.
The top analyst upgrades, downgrades and other research calls from Wednesday include Apple, Caterpillar, Pfizer, Royal Caribbean, Shopify, Under Armour and Walmart.
Pharmaceuticals maker Pfizer reported second-quarter earnings before markets opened Tuesday, beating profit estimates by a penny a share, but coming up short on revenues.
24/7 Wall St. has put together a quick preview Apple, Pfizer, Tesla and some of the other top companies reporting their latest quarterly results in the coming week.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
These five top stocks rated Buy all pay good dividends and offer a degree of safety in what is clearly a very expensive market by historical standards.
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second....
Stocks were indicated marginally higher on Thursday after the European Central Bank statement remained quite dovish. The major equity indexes all remain just under all-time highs. Even though this...
IBM, JPMorgan, Pfizer, and Merck were the poorest performing stocks among the Dow 30 on Monday.
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
In an incredible move on Friday, the FDA approved Endari for the treatment of patients age five and older with sickle cell disease to reduce severe complications that are common with the blood...
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.